Hikma launches generic Tracleer
Hikma is introducing bosentan tablets, in dosage strengths of 62.5 mg and 125 mg.
The product is the generic of Actelion’s Tracleer.
Bosentan is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and to decrease clinical worsening.
Tracleer (bosentan) had a market value of $268 million in 2018, according to Johnson & Johnson’s 2018 annual report.
“We are pleased to add bosentan tablets to our U.S. portfolio. This demonstrates our ability to develop technically challenging, differentiated medicines that address health issues impacting a growing number of people, bringing greater value to our customers and patients across the U.S.,” Hikma president of generics Brian Hoffmann said.
No comments found